CPNQ, >=98% (HPLC), solid

CPNQ, >=98% (HPLC), solid

Stock Code: 3573311
Manufacturer Part No: C3118-5MG
Order Now for 21 day delivery
Click Add to Quote for price and delivery
Quantity: - +

Biochem/physiol Actions


Misfolded proteins accumulate in many neurodegenerative diseases, including huntingtin in Huntington′s disease and alpha-synuclein in Parkinson′s disease. The disease-causing proteins can take various conformations and are prone to aggregate and form larger cytoplasmic or nuclear inclusions. CPNQ (B2) was identified as a compound that promotes inclusion formation in cellular models of both Huntington′s disease and Parkinson′s disease. Despite the aggregate-forming specifics the compound prevents huntingtin-mediated proteasome dysfunction and reduces alpha-synuclein-mediated toxicity. These results demonstrate that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington′s and Parkinson′s diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding. The ability of B2 to prevent toxicity, despite increasing inclusions, suggests that inclusions are beneficial rather than toxic, which will be further explored as the molecular target and mechanism. CPNQ (B2) is a desirable tool for both Huntington′s and Parkinson′s research.


Other Notes


Product is air sensitive.


Packaging


5, 25 mg in glass bottle

Colourbrown
Quality Level100
InChI keyKLNPVNZJCWIQSK-UHFFFAOYSA-N
InChI1S/C20H17ClN4O3/c21-15-5-3-14(4-6-15)20(26)24-12-10-23(11-13-24)17-7-8-18(25(27)28)19-16(17)2-1-9-22-19/h1-9H,10-13H2
ManufacturerSIGMA-ALDRICH
SolubilityDMSO: >5 mg/mL, H2O: insoluble ﹤2 mg/mL
Formsolid
Assay≥98% (HPLC)

There are no downloads for this product.